JAK2 and lymphoma: The suppression of cell proliferation in LMP1-expressed lymphoma cells by JAK2 inhibitors, along with the enhancement of chemotherapeutic cytotoxicity, was shown to be a promising strategy in treating EBV-related lymphomas [173].